4//SEC Filing
TOMSICEK MICHAEL JOHN 4
Accession 0001209191-20-049430
CIK 0001674416other
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 4:46 PM ET
Size
13.3 KB
Accession
0001209191-20-049430
Insider Transaction Report
Form 4
TOMSICEK MICHAEL JOHN
Chief Financial Officer
Transactions
- Sale
Common Shares
2020-09-01$92.23/sh−6,400$590,272→ 3,210 total - Exercise/Conversion
Common Shares
2020-09-01$17.75/sh+12,000$213,000→ 12,410 total - Sale
Common Shares
2020-09-01$91.39/sh−2,800$255,892→ 9,610 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-09-01−12,000→ 156,000 totalExercise: $17.75Exp: 2027-11-21→ Common Shares (12,000 underlying) - Sale
Common Shares
2020-09-01$93.18/sh−2,800$260,904→ 410 total
Footnotes (5)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.78 to $91.76, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.80 to $92.72, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.82 to $93.74, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F5]This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001570392
Filing Metadata
- Form type
- 4
- Filed
- Sep 2, 8:00 PM ET
- Accepted
- Sep 3, 4:46 PM ET
- Size
- 13.3 KB